Project Grant R01HL176772
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $718K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- This federal Project Grant award of $644,997.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify proteomic biomarkers that can predict the progression of idiopathic pulmonary fibrosis (IPF), a severe and often fatal lung disease. The research aims to develop non-invasive assessments that can identify individuals at higher risk of developing IPF and those with more progressive forms of the disease, enabling earlier...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...
- This $386,756 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project to develop an exosomic signature for rapidly progressive idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Christina Eckhardt, will leverage existing IPF patient cohorts and data to identify extracellular vesicle-associated microRNAs that can quantify and predict the risk of accelerated IPF...
- This federal Project Grant award for $806,901.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of oxidation-specific IgA antibodies in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The research, conducted by the University of Virginia, aims to elucidate the link between B cells, IgA, and lung fibrosis in IPF, with the goal of providing insight into disease mechanisms and identifying...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This federal Project Grant award of $159,624.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Vanderbilt University Medical Center (VUMC) to investigate the role of hypoxia-inducible factor (HIF) in promoting alveolar regeneration and functional lung repair for patients with idiopathic pulmonary fibrosis (IPF) and other chronic lung diseases. The research aims to explore how modulating upstream disease mechanisms,...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $542,402 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to a research partnership between Henry Ford Health and Michigan State University Health Sciences. The grant aims to identify drug compounds that can reverse profibrotic gene expression patterns in idiopathic pulmonary fibrosis (IPF), a debilitating lung disease with limited treatment options. Through a sub-award, Corewell Health will provide IPF...
- This federal Project Grant award, valued at $583,233.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the role of circulating osteopontin (OPN) and the CD44 receptor on innate immune cells in remote lung inflammation following acute kidney injury. The overall goal is to develop novel strategies to prevent or treat secondary organ complications in multi-organ failure. Key objectives include: 1) identifying lung...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...